Bridging Clinical Practice and Drug Development, Ora Appoints Dr. John Trein as Therapeutic Lead, Posterior

BOSTON--(BUSINESS WIRE)--Aug 18, 2026--

Ora, the world's leading ophthalmic contract research organization and product development firm, today announced the appointment of João ( John) Trein, MD, MpH, as Therapeutic Lead, Posterior, further strengthening the company's leadership in retinal disease and posterior segment drug development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818980718/en/

A fellowship-trained ophthalmologist and practicing retina specialist, Dr. Trein brings more than 20 years of clinical, surgical, and research experience across retinal diseases, combined with extensive expertise in ophthalmic drug development and global clinical trials. In his new role, he will provide strategic scientific and clinical leadership across Ora's posterior segment programs, helping innovators optimize study design, endpoint strategy, patient identification, safety oversight, and program execution.

"John brings a rare combination of deep clinical expertise, development experience, and a true understanding of the patient journey," said Gustavo De Moraes, MD, PhD, MPH, Chief Medical Officer at Ora. "Having served as both a practicing retina specialist and a trusted advisor to innovators around the world, he is uniquely positioned to help clients navigate increasingly complex retinal development programs. We're thrilled to have him in this leadership role."

Dr. Trein has extensive experience across a broad range of retinal conditions, including geographic atrophy, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vascular disorders, and inherited retinal diseases. His career has spanned clinical practice, surgical care, clinical research, and therapeutic development, providing him with a well-rounded perspective on bringing new treatments to patients.

Prior to assuming this role, Dr. Trein served as Ora's Medical Monitor and Head of Latin America Operations, supporting global ophthalmic programs and advising on protocol development, patient eligibility, imaging and functional endpoints, safety reviews, and operational strategy across multiple retinal indications.

"Retinal innovation is advancing rapidly, creating tremendous opportunities for patients and development teams alike," said Dr. Trein. "Ora's scientific depth, ophthalmology-exclusive focus, and commitment to solving complex development challenges make it an exciting place to help shape the future of retinal therapeutics. I look forward to partnering with innovators across the globe to advance programs that can make a meaningful difference for patients."

In addition to his work at Ora, Dr. Trein actively practices as a retina specialist at Aran Eye Associates in South Florida, providing ongoing care to patients with retinal and vitreous diseases. His continued clinical practice helps ensure that development strategies remain grounded in real-world patient needs and treatment experiences.

Before joining Ora, Dr. Trein owned and operated a specialized ophthalmology practice in Brazil for more than 16 years, performing retina and cataract surgery and caring for patients with complex ophthalmic conditions. He has also been actively involved in physician education, surgical training, and ophthalmic research throughout his career.

Dr. Trein earned his medical degree from the Pontifical Catholic University of Rio Grande do Sul (PUCRS), completed his ophthalmology residency and retina fellowship at the University of São Paulo, and later earned a Master of Pharmaceutical Sciences focused on Clinical and Industrial Drug Development from the University of Cincinnati. Fluent in English, Portuguese, and Spanish, he brings a global perspective and patient-centered approach to advancing retinal therapies.

About Ora

Ora is the world’s leading full-service ophthalmic drug and device CRO with employees in over 20 countries around the world. For over 50 years, we have proudly helped our clients earn more than 90 ophthalmic product approvals. We support a wide array of innovators and organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring new products from concept to market. Ora’s unique methodologies, clinical models, and regulatory strategies have been refined and proven across thousands of global projects. For more information, please visit www.oraclinical.com and follow us on LinkedIn.

João (John) Trein Jr, MD, MpH, Ophthalmologist and Retina Specialist

ISLAMABAD (AP) — Pakistan’s Supreme Court on Tuesday ordered authorities to take imprisoned former Prime Minister Imran Khan to a private hospital in the capital for a medical examination, following months of concerns from his family and personal physicians about his health and access to medical care, his lawyers and party officials said.

A three-judge panel ordered that Khan be taken to Shifa International Hospital in Islamabad in the coming days and examined by a medical board that will include specialists and one of his personal physicians, Faisal Sultan.

The court also ordered prison officials to allow Khan weekly meetings with family members and telephone calls with his sons. Khan’s family has been struggling to secure access to him and have him examined by physicians of his choice.

Pakistan barred visitors earlier this year after receiving intelligence reports about a possible attack on the prison where he is being held.

The order came months after Khan petitioned the court, asking to be transferred from a high-security prison in the nearby garrison city of Rawalpindi to a hospital and to be allowed access to his personal physicians, family and lawyers.

The court said the order was being issued because Khan’s health was at stake and access to medical care is protected under Pakistan’s constitution, according to Khan’s lawyer Salman Akram Raja.

He urged Khan’s supporters not to gather outside the hospital when the former premier is taken there, saying they should avoid inconveniencing other patients.

Earlier this year, Khan was repeatedly taken to a government hospital for treatment of an eye condition.

Concerns about Khan’s health intensified in late January after his family said he had lost about 85% of the vision in his right eye, an assertion the government disputed. Authorities later said Khan regained about 70% of the vision in the eye and that his condition was improving.

The former cricket star turned politician has been in prison since 2023 after being convicted in a graft case. He was removed from office in a parliamentary no-confidence vote in April 2022. He has alleged that his ouster was the result of a U.S.-backed conspiracy involving political rivals and Pakistan’s former army chief, Qamar Javed Bajwa — allegations denied by Washington, Pakistan’s military and his political opponents.

Despite his legal troubles, Khan remains a central figure in Pakistani politics and retains a large following.

FILE - Pakistan's former Prime Minister Imran Khan gives a press conference at his home, in Lahore, Pakistan, on May 18, 2023. (AP Photo/K.M. Chaudary, File)

People walk past Shifa International Hospital, where imprisoned former Prime Minister Imran Khan will be transferred for a medical examination following Pakistan's Supreme Court order, in Islamabad, Pakistan, Tuesday, Aug. 18, 2026. (AP Photo/Anjum Naveed)